49 filings
6-K
PHVS
Pharvaris NV
11 Jun 24
Pharvaris Announces Annual Meeting of Shareholders
6:52am
6-K
PHVS
Pharvaris NV
4 Jun 24
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
4:05pm
6-K
PHVS
Pharvaris NV
8 May 24
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
4:11pm
6-K
PHVS
Pharvaris NV
10 Apr 24
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:11pm
6-K
PHVS
Pharvaris NV
6 Mar 24
Current report (foreign)
4:15pm
6-K
4sh863 8zvms
16 Feb 24
Pharvaris Announces Extraordinary Meeting of Shareholders
6:51am
6-K
9dswha5
7 Feb 24
Registration Rights Agreement
4:01pm
6-K
vfivw2b eq
22 Jan 24
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
6:51am
6-K
bfmo z57ii
8 Jan 24
Current report (foreign)
7:00am
6-K
j7h5k2og 71olyen
8 Dec 23
Current report (foreign)
4:50pm
6-K
gqi14ht
6 Dec 23
Current report (foreign)
6:52am
6-K
458vvi7q1amdr8hacb
2 Nov 23
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
6:51am
6-K
y5r0zhv gn6
7 Aug 23
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update
6:51am
6-K
ipcm2
3 Jul 23
Current report (foreign)
6:50am
6-K
h8v2965kuqlwudmd
27 Jun 23
Current report (foreign)
6:50am
6-K
bn49jz6krfda344phkq
26 Jun 23
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
6:50am
6-K
xfffj
23 Jun 23
Current report (foreign)
10:25am
6-K
rlhf8yxc0zgwd4
20 Jun 23
Current report (foreign)
6:50am
6-K
uthfvbyp
1 Jun 23
Pharvaris Announces Annual Meeting of Shareholders
6:51am
6-K
olbvcye5oxmpov
8 May 23
Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update
6:51am